Evaluation of the American Joint Committee on Cancer (AJCC) 8th Edition Staging System for Hepatocellular Carcinoma in 1,008 Patients with Curative Resection

Sujin Park; Sangjoon Choi; Yoon Ah Cho; Dong Hyun Sinn; Jong Man Kim; Cheol-Keun Park; Sang Yun Ha

doi:10.4143/crt.2020.208

Articles

Page Path: HOME > Cancer Res Treat > Volume 52(4); 2020 > Article

Original Article Gastrointestinal cancer Evaluation of the American Joint Committee on Cancer (AJCC) 8th Edition Staging System for Hepatocellular Carcinoma in 1,008 Patients with Curative Resection: Sujin Park, MD¹, Sangjoon Choi, MD¹, Yoon Ah Cho, MD, PhD¹, Dong Hyun Sinn, MD, PhD², Jong Man Kim, MD, PhD³, Cheol-Keun Park, MD, PhD^1,4, Sang Yun Ha, MD, PhD^1,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2020;52(4):1145-1152.
DOI: https://doi.org/10.4143/crt.2020.208
Published online: April 28, 2020

¹Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

²Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

³Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

⁴Anatomic Pathology Reference Lab, Seegene Medical Foundation, Seoul, Korea

Correspondence: Sang Yun Ha, MD, PhD Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel: 82-2-3410-1586 Fax: 82-2-3410-0025 E-mail: sangyun.ha@skku.edu

• Received: March 10, 2020 • Accepted: April 28, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

8,658 Views
155 Download
28 Web of Science
16 Crossref
29 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Recently, the 8th edition staging system of the American Joint Committee on Cancer (AJCC) for hepatocellular carcinoma (HCC) was released, including a change in T category. We aimed to validate the new AJCC system.
Materials and Methods
The predictive value of the new AJCC was validated in comparison to the previous edition, in a total 1,008 patients who underwent curative resection for HCC as initial treatment.
Results
The 2-year area under the curve values for recurrence-free survival (RFS) and overall survival (OS) were comparable in the 7th and 8th editions. Stage migration was observed in 63 patients (6.3%); from T2 to T1a for 44 patients and from T3 to T4 for 19 patients. The RFS and OS were not different between T1a and T1b in the 8th edition. For solitary tumors ≤ 2 cm, those with microvascular invasion had lower RFS and OS values than those without although they were all classified as T1a in the 8th edition. Tumors involving a major branch of the portal or hepatic vein (T4 by the 8th edition and T3b by the 7th edition) had shorter RFS and OS than multifocal tumors, at least one of which was > 5 cm (T3 by the 8th edition and T3a by the 7th edition).
Conclusion
The AJCC 8th edition staging system for HCC showed comparable predictive performance to the 7th edition. It is desirable in a future revision to consider sub-stratification of solitary tumors ≤ 2 cm (T1a) depending on the presence of vascular invasion, which is not included in the 8th edition.
Key words: Hepatocellular carcinoma, Stage, Prognosis, Microvascular invasion

Introduction

Hepatocellular carcinoma (HCC) comprises 75%-85% of primary liver cancer, which is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer death worldwide [1].

Although hepatic resection is the treatment of choice in HCC, it is not curative because of the high recurrence rate of up to 70% [2]. Therefore, prediction of recurrence and appropriate treatment are important for improved patient outcomes [3].

Among multiple staging systems proposed for stratifying patients with HCC, the American Joint Committee on Cancer (AJCC) staging system for HCC is one of the most commonly used, and the 7th edition of the AJCC system has been validated by various external studies in terms of usefulness and clinical relevance [4-6].

As of January 1, 2018, AJCC 8th edition staging has been used for cancer staging, and there were some notable changes in the T category of HCC compared to the previous version [7,8]. First, solitary tumors with size up to 2 cm are now staged as T1a regardless of the presence of microvascular invasion, unlike in the previous 7th edition, where the presence of microvascular invasion determined whether the tumor is T1 or T2 based on size 2 cm or less. Second, categories named T3b and T4 in the 7th edition are merged into a single T4 category in the new edition and T3a of the 7th edition is renamed as T3 in the 8th edition.

In this study, we validated the predictive value of the new AJCC 8th staging system in comparison to the previous 7th edition in a single-institution study population of 1,008 cases. We also attempted to determine how the change in T category predicts prognosis in this population.

Materials and Methods

1. Study patients

Between January 2008 and December 2012, a total of 1,297 patients underwent hepatic resection for HCC at Samsung Medical Center. Initially, 166 liver transplantation (LT) cases were excluded from the study; among the 1,131 non-LT cases, 89 were excluded because they were treated with other modalities before surgery. Other treatment modalities included transarterial chemoembolization, radiofrequency ablation (RFA) and chemotherapy. Two patients were additionally excluded due to previous operative history and intraoperative RFA, respectively. Among the remaining 1,040 patients who underwent hepatic resection as the initial curative treatment for HCC, an additional 32 patients were excluded as follows: five patients died within 30 days after hepatic resection, three patients showed positive resection margins on pathologic examination, and 24 patients had lymph node metastasis or distant metastasis. Finally, 1,008 cases that were appropriate for tumor staging for HCC were considered in retrospective analysis. The process of case selection is summarized in Fig. 1.

2. Clinicopathologic data acquisition and tumor staging

The medical records of patients meeting all inclusion criteria were reviewed for demographic information of sex, age, and clinically underlying etiology of chronic liver disease, if present. The histopathologic features of HCC are collected by reviewing the pathology reports as follow: tumor number, maximal tumor size, differentiation, microvascular invasion, and major branch of portal vein invasion, and the T category was determined using the 7th and 8th editions of the AJCC staging system [7,8]. Presence of chronic hepatitis and fibrosis stage in the background liver parenchyma was also evaluated. The histological differentiation of HCC was graded by the Edmondson and Steiner system, which classifies HCC into four grades from I to IV [9].

3. Surveillance for tumor recurrence and survival

After surgical resection for HCC, the patients were regularly monitored by dynamic contrast-enhanced computer tomography (CT) and/or magnetic resonance imaging (MRI) and a serum tumor marker such as α-fetoprotein every 3 to 6 months. Diagnosis of recurrence was dependent on radiologic evaluation of CT and/or MRI results. Survival data such as overall survival (OS) and recurrence-free survival (RFS) were also recorded. The durations of RFS and OS were calculated from the date of surgical resection to the date of each event or the last day of follow-up, respectively.

4. Statistical analysis

RFS and OS were estimated using the Kaplan-Meier method and compared by log-rank test. SPSS Statistics ver. 25.0 (IBM Inc., Armonk, NY) was utilized in this analysis. Analysis of the time-dependent receiver operating characteristic (ROC) curves for censored survival data was used to compare the capability of the two models to predict tumor recurrence. This analysis was executed using SAS ver. 9.4 (SAS Institute Inc., Cary, NC) and R 3.6.1 (Vienna, Austria; http://www.R-project.org/). All p-values lower than 0.05 were considered statistically significant.

5. Ethical statement

The Institutional Review Board of Samsung Medical Center approved this study and waived informed consent (IRB No. 2019-08-018).

Results

1. Patients and characteristics

The median age of 1,008 patients was 56 years (range, 20 to 83 years), 816 patients (81.0%) were male and 192 patients (19.0%) were female. The median follow-up period was 64.8 months (standard deviation, 29.7 months; range, 0.7 to 112.5 months). The characteristics of the 1,008 enrolled cases are summarized in Table 1.

2. Stage distribution and migration

When staged by the AJCC 7th edition, the distribution of T category was as follows: T1 (n=472, 46.8%), T2 (n=477, 47.3%), T3a (n=35, 3.5%), T3b (n=19, 1.9%), and T4 (n=5, 0.5%). When the 8th edition was applied to our study population, the distribution was as follows: T1a (n=201, 19.9%), T1b (n=315, 31.3%), T2 (n=433, 43.0%), T3 (n=35, 3.5%), and T4 (n=24, 2.4%) (Table 2).

Among 472 patients who were staged as T1 by the 7th edition, 157 were reclassified as T1a by the 8th edition, and 315 were reclassified as T1b. Stage migration was also observed. Among the 477 patients that were staged as T2 by the 7th edition, 44 patients migrated to T1a when staged by the 8th edition. Additionally, among 54 patients that were previously staged as T3, 19 migrated to T4 when staged by the 8th edition. In total, the T categories of 63 patients (6.3% of 1,008 patients) were scored differently by the 7th and 8th editions.

3. Prognostic effect of T category in the 7th and 8th editions

The 1-, 3-, and 5-year RFS rates were 74.7%, 55.6%, and 37.9%, respectively, while those of OS were 93.3%, 79.4%, and 58.1%. The survival curves according to the 7th and 8th editions are shown in Figs. 2 and 3. Overall, RFS and OS were different according to T category of both the 7th and 8th editions. However, they were not different between T3b and T4 with the 7th edition or between T1a and T1b in the 8th edition.

According to the survival curves by the 7th edition, both RFS and OS were different between T3a and T3b (p=0.015 for RFS and p=0.035 for OS), but they were not significantly different between T3a and T4 (p=0.306 for RFS and p=0.055 for OS) or T3b and T4 (p=0.886 for RFS and p=0.559 for OS). According to the survival curves for the 8th edition, however, both RFS and OS were not different between T1a and T1b (p=0.380 for RFS and p=0.777 for OS).

The area under the ROC curve (AUC) graphs for recurrence and death were obtained for both the 7th and 8th editions (Fig. 4). The 2-year AUC value for RFS was 0.693 by the 7th edition and 0.690 by the 8th edition (p=0.737). Similarly, the 2-year AUC value for OS was 0.770 by the 7th edition and 0.765 by the 8th edition (p=0.715). These results indicate comparable predictive abilities of T staging by the AJCC 7th and 8th editions in HCC.

4. Prognostic effect of microvascular invasion in HCC ≤ 2 cm

The tumor sizes of 224 cases (22.2% of the 1,008 cases) were 2 cm or less; among these, 201 cases (19.9%) were solitary tumors that were staged as T1a by the AJCC 8th edition. Although they were staged the same, when these 201 cases were classified into two groups according to presence of microvascular invasion, both RFS and OS were statistically significantly lower in the group with microvascular invasion (n=157) than in those without microvascular invasion (n=44) (p=0.037 for RFS and p < 0.001 for OS) (Fig. 5).

5. Involvement of a major branch of the portal or hepatic vein

Of all tumors, 19 (1.9%) involved a major branch of portal vein or hepatic vein and showed T-category migration from T3b by 7th to T4 by the 8th edition. The patients with these tumors had significantly lower RFS and OS values than the 35 cases (34.7%) with multifocal tumors, at least one of which was larger than 5 cm and were classified as T3a by the 7th edition and T3 by the 8th edition (p=0.015 for RFS and p=0.035 for OS) (Fig. 6). These results support the change of 8th edition.

Discussion

The prognostic effect of microvascular invasion has been reported in several previous studies as a negative effector in patient survival [10-12]. A recent meta-analysis study incorporating 14 studies involving 3,033 patients confirmed this issue [13]. However, it is debatable that the prognostic effect of microvascular invasion in small-size HCC ≤ 2 cm is significant. In one study published in 2013 by Shindoh et al. [14], however, the long-term survival of 155 patients (14.0%) with solitary HCC ≤ 2 cm was not affected by microvascular invasion. Based on these data, a part of the pathologic T category was modified from the AJCC 7th edition to the 8th edition. According to the 7th edition, a T1 tumor refers only to a solitary tumor without vascular invasion. If there is vascular invasion, it is staged as T2 even if the tumor is solitary. But, in the 8th edition, the size of the tumor is the determining factor, and all solitary tumors with size 2 cm or less are staged as T1a regardless of the presence of vascular invasion. Tumors are staged as at least T1b when their size is larger than 2 cm, and the presence of vascular invasion determines whether the tumor is T1b or T2. In short, in smaller tumors that are 2 cm or less, the presence of vascular invasion is not considered as a prognostic factor in the updated AJCC 8th edition.

One of the main findings of our study was that solitary tumors ≤ 2 cm with microvascular invasion showed lower RFS and OS values than those without microvascular invasion. The discrepancy between the studies by Shindoh et al. [14] and our group may have been caused by the characteristics of the study population, since people in South Korea receive medical services from tertiary medical institutions due to the national health insurance system. Thus, early-stage cancers can be detected more frequently. The proportion of solitary tumors ≤ 2 cm was higher in our study than in the study by Shindoh et al. [14] (19.9% vs. 14.0%, p < 0.001). Another possible explanation is that there is no standardized guideline for pathologic evaluation of microvascular invasion, but this effect might be limited because the frequency of microvascular invasion in solitary HCC ≤ 2 cm was comparable in these two studies (26.5% vs. 22.3%, p=0.48).

There are some reports supporting our results. Recently, Wang et al. [15] demonstrated that microvascular invasion predicts poor prognosis of solitary HCC ≤ 2 cm based on propensity score matching analysis of 496 patients. Meta-analyses by Chen et al. [13] also showed a prognostic effect of microvascular invasion in solitary HCC ≤ 2 cm.

Another major change in T staging is that T3a in the 7th edition is now re-categorized as T3 in the 8th edition, and tumors involving a major branch of the portal or hepatic vein, which were categorized as T3b in the 7th edition, are reclassified as T4 in the 8th edition. This change was based on a long-term survival study of 754 patients [16], which showed no survival difference between patients with T3a and those with T3b tumors (p=0.073) or between patients with T3b and those with T4 tumors (p=0.227). In our study, tumors involving a major branch of the portal or hepatic vein (T4 by the 8th edition and T3b by the 7th edition, n=19) showed lower RFS and OS than multifocal tumors, at least one of which was > 5 cm (T3 by the 8th edition and T3a by the 7th edition, n=35) (p=0.015 for RFS and p=0.035 for OS), supporting the change in the 8th edition.

In the RFS and OS curves generated according to AJCC 7th edition T staging (Fig. 2), the curves of the T4 tumors did not follow the estimated survival. Since the inclusion criteria of this study were designed to strictly involve only resectable cases, there are only five cases staged as T4 after resection. The key information related to these T4 tumors is summarized in S1 Table. As described above, neither RFS nor OS was different between T3a and T4 (p=0.055 for RFS and p=0.306 for OS) or T3b and T4 (p=0.886 for RFS and p=0.559 for OS) by the 7th edition. Therefore, although it was a small group, our results related to T4 tumors suggest that tumors involving a major branch of the portal vein or hepatic vein (T3b) may not show better prognosis in the long term than those involving adjacent organs (other than gallbladder) to a resectable extent. This idea is consistent with the change of AJCC staging, since T3b and T4 categories in the 7th edition are merged into the same T4 category in the 8th edition.

The major limitation of this study is that only curatively resected HCCs were enrolled for analysis. Surgical resection is the only modality with which we can definitely determine the presence of microvascular invasion by pathologic evaluation. Since HCCs can be treated by various treatment modalities based on the status of the patients, study population should be extended to overcome this limitation. In further studies, population-based or multicenter analysis that also include HCC cases treated with other modalities other than surgical resection is required to validate the findings of this study and eventually to modify future AJCC staging systems of HCC with the results.

The T category of AJCC 8th edition had comparable predictive performance to the 7th edition, and T4 in the 8th edition, which was established by combining T3b and T4 of the 7th edition, better predicted the prognosis of tumors with higher T category. However, presence of microvascular invasion still has prognostic value in smaller solitary tumors (size ≤ 2 cm), which are all staged as T1a by the AJCC 8th edition. Further studies such as population-based or multicenter analysis incorporating of HCCs with various treatment modalities other than surgical resection are required to validate these findings and to apply the results to future AJCC staging systems for HCC.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

S1 Table.

Clinicopathologic features of cases with T4 by American Joint Committee on Cancer (AJCC) 7th edition staging system

crt-2020-208-suppl.pdf

NOTES

Conflicts of interest relevant to this article was not reported.

Acknowledgements

This study was funded by the Samsung Medical Center intramural Grant (#SMO1161731) and the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2017R1C1B5017890).

Fig. 1.

Summary of patient selection. HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; RFA, radiofrequency ablation.

Fig. 2.

Kaplan-Meir survival curves according to the American Joint Committee on Cancer T category of the 7th edition: recurrence-free survival (A) and overall survival (B).

Fig. 3.

Kaplan-Meir survival curves according to the American Joint Committee on Cancer T category of the 8th edition: recurrence-free survival (A) and overall survival (B).

Fig. 4.

The area under the curve graphs for recurrence (A) and death (B) by the 7th and 8th editions of the American Joint Committee on Cancer (AJCC) T category.

Fig. 5.

Kaplan-Meir survival curves of single hepatocellular carcinoma ≤ 2 cm according to presence of microvascular invasion: recurrence-free survival (A) and overall survival (B).

Fig. 6.

Kaplan-Meir survival curves of the American Joint Committee on Cancer T category 3a versus 3b of the 7th edition: recurrence-free survival (A) and overall survival (B).

Table 1.

Summary of clinicopathologhic characteristics of the patients

Characteristic	No. (%)
Sex
Male	816 (81.0)
Female	192 (19.0)
Age, median (range, yr)	56 (20-83)
Tumor numbers
Solitary	876 (86.9)
Multifocal	132 (13.1)
Tumor size (cm)
≤ 2	224 (22.2)
> 2 and ≤ 5	554 (55.0)
> 5	230 (22.8)
Edmondson grade
I	63 (6.3)
II	872 (86.5)
III	68 (6.7)
IV	5 (0.5)
Microvascular invasion
(–)	520 (51.6)
(+)	488 (48.4)
Major branch of portal vein invasion
(–)	989 (98.1)
(+)	19 (1.9)
7th AJCC T category
T1	472 (46.8)
T2	477 (47.3)
T3a	35 (3.5)
T3b	19 (1.9)
T4	5 (0.5)
8th AJCC T category
T1a	201 (19.9)
T1b	315 (31.3)
T2	433 (43.0)
T3	35 (3.5)
T4	24 (2.4)
Etiology
HBV	812 (80.6)
HCV	45 (4.5)
HBV and HCV	4 (0.3)
Alcohol	34 (3.4)
Others	113 (11.2)
Fibrosis stage
No cirrhosis	564 (56.0)
Cirrhosis	443 (44.0)
Non-diagnostic^a)	1 (0.0)
Recurrence
(–)	584 (57.9)
(+)	424 (42.1)
Death
(–)	792 (78.6)
(+)	216 (21.4)

AJCC, American Joint Committee on Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus.

^a) Evaluation of fibrosis was limited due to insufficient background not-tumor tissue in one case.

Table 2.

Distribution and migration of T category according to American Joint Committee on Cancer (AJCC) 7th and 8th edition staging system

	Pathologic T category by AJCC 8th edition					Total
	T1a	T1b	T2	T3	T4	Total
Pathologic T category by AJCC 7th edition
T1	157	315	0	0	0	472
T2	44	0	433	0	0	477
T3a	0	0	0	35	0	35
T3b	0	0	0	0	19	19
T4	0	0	0	0	5	5
Total	201	315	433	35	24	1,008

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. Article PubMed
2. Sherman M. Recurrence of hepatocellular carcinoma. N Engl J Med. 2008;359:2045–7. Article PubMed
3. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic imp-lications. Ann Surg. 2006;243:229–35. Article PubMed PMC
4. Cheng CH, Lee CF, Wu TH, Chan KM, Chou HS, Wu TJ, et al. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol. 2011;9:114.Article PubMed PMC
5. Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, et al. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer. 2007;120:2650–5. Article PubMed
6. Varotti G, Ramacciato G, Ercolani G, Grazi GL, Vetrone G, Cescon M, et al. Comparison between the fifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: multicentric study on 393 cirrhotic resected patients. Eur J Surg Oncol. 2005;31:760–7. Article PubMed
7. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.
8. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
9. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462–503. Article PubMed
10. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–6. Article PubMed
11. Barreto SG, Brooke-Smith M, Dolan P, Wilson TG, Padbury RT, Chen JW. Cirrhosis and microvascular invasion predict outcomes in hepatocellular carcinoma. ANZ J Surg. 2013;83:331–5. Article PubMed
12. Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20:325–39. Article PubMed PDF
13. Chen ZH, Zhang XP, Wang H, Chai ZT, Sun JX, Guo WX, et al. Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis. HPB (Oxford). 2019;21:935–44. Article PubMed
14. Shindoh J, Andreou A, Aloia TA, Zimmitti G, Lauwers GY, Laurent A, et al. Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol. 2013;20:1223–9. Article PubMed PDF
15. Wang H, Wu MC, Cong WM. Microvascular invasion predicts a poor prognosis of solitary hepatocellular carcinoma up to 2 cm based on propensity score matching analysis. Hepatol Res. 2019;49:344–54. Article PubMed
16. Chan AC, Fan ST, Poon RT, Cheung TT, Chok KS, Chan SC, et al. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB (Oxford). 2013;15:439–48. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Improving Adherence of Young Male Patients with HBV Infection to the Regular Follow-Up via Mobile Healthcare Platform Might Be Cost-Effective to Decrease the Morbidity of Advanced Liver Cancer
Hao Liang, Min Yang, Dan Luo, Ya-Kun Wu
Patient Preference and Adherence.2024; Volume 18: 2581. CrossRef
Prognostic impact of tumor size on isolated hepatocellular carcinoma without vascular invasion may have age variance
Yi Zhang, Jun-Gang Zhang, Wei Yu, Lei Liang, Chun Wu, Cheng-Wu Zhang, Ya-Ming Xie, Dong-Sheng Huang, Ying Shi
Frontiers in Surgery.2023;[Epub] CrossRef
Advances in post-operative prognostic models for hepatocellular carcinoma
Ziqin He, Xiaomin She, Ziyu Liu, Xing Gao, Lu Lu, Julu Huang, Cheng Lu, Yan Lin, Rong Liang, Jiazhou Ye
Journal of Zhejiang University-SCIENCE B.2023; 24(3): 191. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Journal of Liver Cancer.2023; 23(1): 1. CrossRef
Overall survival among patients who undergo resection does not differ significantly between T1a and T1b hepatocellular carcinoma based on the 8th American Joint Commission on Cancer
Yueh-Wei Liu, Wei-Feng Li, Fang-Ying Kuo, Hock-Liew Eng, Chih-Chi Wang, Chih-Che Lin, Chee-Chien Yong, Yi-Hao Yen
Langenbeck's Archives of Surgery.2023;[Epub] CrossRef
Perfusion parameters of triphasic computed tomography hold preoperative prediction value for microvascular invasion in hepatocellular carcinoma
Li Zhang, Guodong Pang, Jing Zhang, Zhenguo Yuan
Scientific Reports.2023;[Epub] CrossRef
AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma
Diwakar Suresh, Akshatha N. Srinivas, Akila Prashant, Suchitha Satish, Prashant Vishwanath, Suma M. Nataraj, Srinivas V. Koduru, Prasanna K. Santhekadur, Divya P. Kumar
Frontiers in Oncology.2023;[Epub] CrossRef
ESR1 Regulates the Obesity- and Metabolism-Differential Gene MMAA to Inhibit the Occurrence and Development of Hepatocellular Carcinoma
Yiyin Zhang, Jiaxi Cheng, Cheng Zhong, Qiming Xia, Yirun Li, Peng Chen, Xiaoxiao Fan, Qijiang Mao, Hui Lin, Defei Hong
Frontiers in Oncology.2022;[Epub] CrossRef
Efficacy of Postoperative Adjuvant Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients With Microscopic Portal Vein Invasion
Yiwen Qiu, Yi Yang, Tao Wang, Shu Shen, Wentao Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Nomogram Based on Inflammatory Biomarkers to Predict the Recurrence of Hepatocellular Carcinoma—A Multicentre Experience
Zehao Zheng, Renguo Guan, Yiping Zou, Zhixiang Jian, Ye Lin, Rongping Guo, Haosheng Jin
Journal of Inflammation Research.2022; Volume 15: 5089. CrossRef
CSTF2 Acts as a Prognostic Marker Correlated with Immune Infiltration in Hepatocellular Carcinoma
Wang Zhang, Yipeng Wan, Yue Zhang, Qi Liu, Xuan Zhu
Cancer Management and Research.2022; Volume 14: 2691. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
Revisiting Surgical Strategies for Hepatocellular Carcinoma With Microvascular Invasion
Er-lei Zhang, Qi Cheng, Zhi-yong Huang, Wei Dong
Frontiers in Oncology.2021;[Epub] CrossRef
Two-Trait Predictor of Venous Invasion on Contrast-Enhanced CT as a Preoperative Predictor of Outcomes for Early-Stage Hepatocellular Carcinoma After Hepatectomy
Xinming Li, Xuchang Zhang, Zhipeng Li, Chuanmiao Xie, Shuping Qin, Meng Yan, Qiying Ke, Xuan Jin, Ting Lin, Muyao Zhou, Wen Liang, Zhendong Qi, Zhijun Geng, Xianyue Quan
Frontiers in Oncology.2021;[Epub] CrossRef
Construction and Validation of an Immune Cell Signature Score to Evaluate Prognosis and Therapeutic Efficacy in Hepatocellular Carcinoma
Linfeng Xu, Xingxing Jian, Zhenhao Liu, Jingjing Zhao, Siwen Zhang, Yong Lin, Lu Xie
Frontiers in Genetics.2021;[Epub] CrossRef
Up-to-date Knowledge on the Pathological Diagnosis of Hepatocellular Carcinoma
Ji Hae Nahm, Young Nyun Park
The Korean Journal of Gastroenterology.2021; 78(5): 268. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Evaluation of the American Joint Committee on Cancer (AJCC) 8th Edition Staging System for Hepatocellular Carcinoma in 1,008 Patients with Curative Resection

Cancer Res Treat. 2020;52(4):1145-1152. Published online April 28, 2020

DOI: https://doi.org/10.4143/crt.2020.208

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Evaluation of the American Joint Committee on Cancer (AJCC) 8th Edition Staging System for Hepatocellular Carcinoma in 1,008 Patients with Curative Resection

Fig. 1. Summary of patient selection. HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; RFA, radiofrequency ablation.

Fig. 2. Kaplan-Meir survival curves according to the American Joint Committee on Cancer T category of the 7th edition: recurrence-free survival (A) and overall survival (B).

Fig. 3. Kaplan-Meir survival curves according to the American Joint Committee on Cancer T category of the 8th edition: recurrence-free survival (A) and overall survival (B).

Fig. 4. The area under the curve graphs for recurrence (A) and death (B) by the 7th and 8th editions of the American Joint Committee on Cancer (AJCC) T category.

Fig. 5. Kaplan-Meir survival curves of single hepatocellular carcinoma ≤ 2 cm according to presence of microvascular invasion: recurrence-free survival (A) and overall survival (B).

Fig. 6. Kaplan-Meir survival curves of the American Joint Committee on Cancer T category 3a versus 3b of the 7th edition: recurrence-free survival (A) and overall survival (B).

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Evaluation of the American Joint Committee on Cancer (AJCC) 8th Edition Staging System for Hepatocellular Carcinoma in 1,008 Patients with Curative Resection

Characteristic	No. (%)
Sex
Male	816 (81.0)
Female	192 (19.0)
Age, median (range, yr)	56 (20-83)
Tumor numbers
Solitary	876 (86.9)
Multifocal	132 (13.1)
Tumor size (cm)
≤ 2	224 (22.2)
> 2 and ≤ 5	554 (55.0)
> 5	230 (22.8)
Edmondson grade
I	63 (6.3)
II	872 (86.5)
III	68 (6.7)
IV	5 (0.5)
Microvascular invasion
(–)	520 (51.6)
(+)	488 (48.4)
Major branch of portal vein invasion
(–)	989 (98.1)
(+)	19 (1.9)
7th AJCC T category
T1	472 (46.8)
T2	477 (47.3)
T3a	35 (3.5)
T3b	19 (1.9)
T4	5 (0.5)
8th AJCC T category
T1a	201 (19.9)
T1b	315 (31.3)
T2	433 (43.0)
T3	35 (3.5)
T4	24 (2.4)
Etiology
HBV	812 (80.6)
HCV	45 (4.5)
HBV and HCV	4 (0.3)
Alcohol	34 (3.4)
Others	113 (11.2)
Fibrosis stage
No cirrhosis	564 (56.0)
Cirrhosis	443 (44.0)
Non-diagnostic^a)	1 (0.0)
Recurrence
(–)	584 (57.9)
(+)	424 (42.1)
Death
(–)	792 (78.6)
(+)	216 (21.4)

	Pathologic T category by AJCC 8th edition					Total
	T1a	T1b	T2	T3	T4	Total
Pathologic T category by AJCC 7th edition
T1	157	315	0	0	0	472
T2	44	0	433	0	0	477
T3a	0	0	0	35	0	35
T3b	0	0	0	0	19	19
T4	0	0	0	0	5	5
Total	201	315	433	35	24	1,008

Table 1. Summary of clinicopathologhic characteristics of the patients

AJCC, American Joint Committee on Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus.

Evaluation of fibrosis was limited due to insufficient background not-tumor tissue in one case.

Table 2. Distribution and migration of T category according to American Joint Committee on Cancer (AJCC) 7th and 8th edition staging system